A novel plier-like gemini cationic niosome for nucleic acid delivery

Pengnam, Supusson; Patrojanasophon, Prasopchai; Rojanarata, Theerasak; Ngawhirunpat, Tanasait; Yingyongnarongkul, Boon‐ek; Radchatawedchakoon, Widchaya; Opanasopit, Praneet

doi:10.1016/j.jddst.2019.04.032

Cited by 20 publications

(8 citation statements)

References 37 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, this was achieved at a weight ratio of 10 in comparison to that of the normal cationic niosomes of 2.5. The study further confirmed the protection of pDNA from serum nuclease for at least 6 h by the PEGylated niosomes [ 113 ].…”

Section: Specialised Niosomessupporting

confidence: 67%

See 1 more Smart Citation

Current Advances in Specialised Niosomal Drug Delivery: Manufacture, Characterization and Drug Delivery Applications

Witika

Bassey

Demana

et al. 2022

IJMS

View full text Add to dashboard Cite

Development of nanomaterials for drug delivery has received considerable attention due to their potential for achieving on-target delivery to the diseased area while the surrounding healthy tissue is spared. Safe and efficiently delivered payloads have always been a challenge in pharmaceutics. Niosomes are self-assembled vesicular nanocarriers formed by hydration of a non-ionic surfactant, cholesterol or other molecules that combine to form a versatile drug delivery system with a variety of applications ranging from topical delivery to targeted delivery. Niosomes have advantages similar to those of liposomes with regards to their ability to incorporate both hydrophilic and hydrophobic payloads. Moreover, niosomes have simple manufacturing methods, low production cost and exhibit extended stability, consequently overcoming the major drawbacks associated with liposomes. This review provides a comprehensive summary of niosomal research to date, including the types of niosomes and critical material attributes (CMA) and critical process parameters (CPP) of niosomes and their effects on the critical quality attributes (CQA) of the technology. Furthermore, physical characterisation techniques of niosomes are provided. The review then highlights recent applications of specialised niosomes in drug delivery. Finally, limitations and prospects for this technology are discussed.

show abstract

Section: Specialised Niosomessupporting

confidence: 67%

“…Pengnam et al [ 113 ] reported the use of PEGylated niosomes to overcome these challenges—PEGylated plier-like cationic niosomes containing Span ® 20 and cholesterol for gene delivery were studied. The resultant cationic nioplexes showed a positive zeta potential that decreased with an increase in the amount of PEG added.…”

Section: Specialised Niosomesmentioning

confidence: 99%

Current Advances in Specialised Niosomal Drug Delivery: Manufacture, Characterization and Drug Delivery Applications

Witika

Bassey

Demana

et al. 2022

IJMS

View full text Add to dashboard Cite

show abstract

“…A flow cytometry assay was then used to confirm the transfection of pEGFP-C2. The percentage of the GFP cells and the mean fluorescence intensity (MFI) 48,49 of lipoplexes 4A at different percentages of the serum and cell lines are shown in Fig. 6.…”

Section: In Vitro Gene Transfectionmentioning

confidence: 99%

The effect of polar headgroups and spacer length on the DNA transfection of cholesterol-based cationic lipids

et al. 2020

Self Cite

View full text Add to dashboard Cite

show abstract

“…The authors previously reported a novel cationic lipid that can be used to prepare cationic niosomes containing plier-like cationic lipid B (PCN-B). It can be used effectively for the delivery of siRNA with high transfection efficiency and minimal cytotoxicity in a green fluorescent screening model [ 41 , 42 ]. The anticancer effect of siRNA against anti-apoptotic genes, namely, Mcl-1, Bcl-2, and survivin, were first screened in breast cancer cell line MCF-7 and MDA-MB-231.…”

Section: Introductionmentioning

confidence: 99%

Synergistic Effect of Doxorubicin and siRNA-Mediated Silencing of Mcl-1 Using Cationic Niosomes against 3D MCF-7 Spheroids

et al. 2021

Self Cite

View full text Add to dashboard Cite

Chemotherapy is a vital option for cancer treatment; however, its therapeutic outcomes are limited by dose-dependent toxicity and the occurrence of chemoresistance. siRNAs have emerged as an attractive therapeutic option enabling specific interference with target genes. Combination therapy using chemotherapeutic agents along with gene therapy could be a potential strategy for cancer management, which not only improves therapeutic efficacy but also decreases untoward effects from dose reduction. In this study, a cationic niosome containing plier-like cationic lipid B was used to convey siRNA against anti-apoptotic mRNA into MCF-7 and MDA-MB-231 cells. Mcl-1 silencing markedly decreased the viability of MCF-7 cells and triggered apoptosis. Moreover, computer modeling suggested that the combination of doxorubicin (Dox) and Mcl-1 siRNA exhibited a synergistic relationship and enabled a dose reduction of each agent at 1.71 and 3.91 folds, respectively, to reach a 90% inhibitory effect when compared to single-agent treatments. Synergistic antitumor activity was further verified in a 3D spheroid culture which revealed, in contrast to single-agent treatment, the combination markedly decreased spheroid volume over time. Together, the combination therapy between Mcl-1 silencing and Dox exhibits a synergistic effect that may be exploited for novel breast cancer treatment.

show abstract

A novel plier-like gemini cationic niosome for nucleic acid delivery

Cited by 20 publications

References 37 publications

Current Advances in Specialised Niosomal Drug Delivery: Manufacture, Characterization and Drug Delivery Applications

Current Advances in Specialised Niosomal Drug Delivery: Manufacture, Characterization and Drug Delivery Applications

The effect of polar headgroups and spacer length on the DNA transfection of cholesterol-based cationic lipids

Synergistic Effect of Doxorubicin and siRNA-Mediated Silencing of Mcl-1 Using Cationic Niosomes against 3D MCF-7 Spheroids

Contact Info

Product

Resources

About